Skip to main content

GeneProt to Build Proteomics Facility and Relocate Headquarters to New Jersey

NEW YORK, Oct. 3 – GeneProt said Wednesday that it will build a high-throughput proteomics laboratory in North Brunswick, NJ, and relocate its corporate headquarters there from Evanston, Ill.

The new facility, located in The Technology Center, a corporate complex owned by the New Jersey Economic Development Authority (NJEDA), will contain instruments and equipment for separating and analyzing proteins, including supercomputing equipment, GeneProt said in a statement.

GeneProt has leased 60,000 square feet of laboratory space in a building still under construction, and will finance the construction of an additional 40,000 square foot, four-story office building for its corporate headquarters. For its immediate needs, the company has leased 3,200 square feet of office space in the complex. 

To encourage the company to relocate to New Jersey, the NJEDA granted the company a construction allowance of $6 million, and an employment incentive grant worth over $3 million over 10 years. "This greatly supports our speed-to-market strategy and allows us to apply resources elsewhere; for example, in recruitment and R&D,” Cédric Loiret-Bernal, GeneProt CEO, said in a statement.

Earlier this year, GeneProt opened its first proteomics analysis facility in Geneva, Switzerland, that holds 51 Bruker Daltonics mass spectrometers for identifying the amino acid sequence of proteins isolated from clinical samples. The company is currently working with Novartis to perform proteomics studies on Novartis’ clinical samples.

The laboratory and corporate offices in North Brunswick will eventually hold about 150 GeneProt employees, the company said. The new facility will be fully operational in early 2002. 

GeneProt chose the new location, near Princeton, NJ, because of its proximity to Princeton University and other academic centers, and because it also close to large pharmaceutical companies located in central New Jersey, the company said.  
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.